Literature DB >> 24145719

Effects of prostaglandin E2 on p53 mRNA transcription and p53 mutagenesis during T-cell-independent human B-cell clonal expansion.

Shabirul Haque1, Xiao Jie Yan, Lisa Rosen, Steven McCormick, Nicholas Chiorazzi, Patricia K A Mongini.   

Abstract

Within T-cell-dependent germinal centers, p53 gene transcription is repressed by Bcl-6 and is thus less vulnerable to mutation. Malignant lymphomas within inflamed extranodal sites exhibit a relatively high incidence of p53 mutations. The latter might originate from normal B-cell clones manifesting activation-induced cytosine deaminase (AID) and up-regulated p53 following T-cell-independent (TI) stimulation. We here examine p53 gene transcription in such TI clones, with a focus on modulatory effects of prostaglandin E2 (PGE2), and evaluate progeny for p53 mutations. Resting IgM(+)IgD(+)CD27(-) B cells from human tonsils were labeled with CFSE and stimulated in vitro with complement-coated antigen surrogate, IL-4, and BAFF ± exogenous PGE2 (50 nM) or an analog specific for the EP2 PGE2 receptor. We use flow cytometry to measure p53 and AID protein within variably divided blasts, qRT-PCR of p53 mRNA from cultures with or without actinomycin D to monitor mRNA transcription/stability, and single-cell p53 RT-PCR/sequencing to assess progeny for p53 mutations. We report that EP2 signaling triggers increased p53 gene transcriptional activity in AID(+) cycling blasts (P<0.01). Progeny exhibit p53 mutations at a frequency (8.5 × 10(-4)) greater than the baseline error rate (<0.8 × 10(-4)). We conclude that, devoid of the repressive influences of Bcl-6, dividing B lymphoblasts in inflamed tissues should display heightened p53 transcription and increased risk of p53 mutagenesis.

Entities:  

Keywords:  B lymphocyte; TP53; eicosanoid; inflammation; lymphoma

Mesh:

Substances:

Year:  2013        PMID: 24145719      PMCID: PMC3898655          DOI: 10.1096/fj.13-237792

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  116 in total

1.  Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription.

Authors:  Jerry E Chipuk; Ulrich Maurer; Douglas R Green; Martin Schuler
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

2.  Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line.

Authors:  Xin-Hua Liu; Alexander Kirschenbaum; Kang Yu; Shen Yao; Alice C Levine
Journal:  J Biol Chem       Date:  2004-11-18       Impact factor: 5.157

3.  Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia.

Authors:  Ola Landgren; Joshua S Rapkin; Neil E Caporaso; Lene Mellemkjaer; Gloria Gridley; Lynn R Goldin; Eric A Engels
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

4.  The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.

Authors:  Ryan T Phan; Riccardo Dalla-Favera
Journal:  Nature       Date:  2004-12-02       Impact factor: 49.962

5.  Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis.

Authors:  Byeong-Seon Jeong; Wenwei Hu; Vladimir Belyi; Raul Rabadan; Arnold J Levine
Journal:  FASEB J       Date:  2009-12-17       Impact factor: 5.191

6.  Two levels of protection for the B cell genome during somatic hypermutation.

Authors:  Man Liu; Jamie L Duke; Daniel J Richter; Carola G Vinuesa; Christopher C Goodnow; Steven H Kleinstein; David G Schatz
Journal:  Nature       Date:  2008-02-14       Impact factor: 49.962

7.  cAMP stimulates the C/EBP-related transcription factor rNFIL-6 to trans-locate to the nucleus and induce c-fos transcription.

Authors:  R Metz; E Ziff
Journal:  Genes Dev       Date:  1991-10       Impact factor: 11.361

8.  Splenic marginal zone B-cell and thymic T-cell lymphomas in p53-deficient mice.

Authors:  J M Ward; L Tadesse-Heath; S N Perkins; S K Chattopadhyay; S D Hursting; H C Morse
Journal:  Lab Invest       Date:  1999-01       Impact factor: 5.662

9.  DNA polymerase eta is the sole contributor of A/T modifications during immunoglobulin gene hypermutation in the mouse.

Authors:  Frédéric Delbos; Said Aoufouchi; Ahmad Faili; Jean-Claude Weill; Claude-Agnès Reynaud
Journal:  J Exp Med       Date:  2006-12-26       Impact factor: 14.307

10.  The activation-induced cytidine deaminase (AID) efficiently targets DNA in nucleosomes but only during transcription.

Authors:  Hong Ming Shen; Michael G Poirier; Michael J Allen; Justin North; Ratnesh Lal; Jonathan Widom; Ursula Storb
Journal:  J Exp Med       Date:  2009-04-20       Impact factor: 14.307

View more
  4 in total

1.  TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.

Authors:  Patricia K A Mongini; Rashmi Gupta; Erin Boyle; Jennifer Nieto; Hyunjoo Lee; Joanna Stein; Jela Bandovic; Tatjana Stankovic; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Charles C Chu; Nicholas Chiorazzi
Journal:  J Immunol       Date:  2015-07-01       Impact factor: 5.422

2.  Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins.

Authors:  Rashmi Gupta; Wentian Li; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2019-04-15       Impact factor: 5.422

Review 3.  Sphingolipids and Lymphomas: A Double-Edged Sword.

Authors:  Alfredo Pherez-Farah; Rosa Del Carmen López-Sánchez; Luis Mario Villela-Martínez; Rocío Ortiz-López; Brady E Beltrán; José Ascención Hernández-Hernández
Journal:  Cancers (Basel)       Date:  2022-04-19       Impact factor: 6.575

4.  Mechanism of QSYQ on anti-apoptosis mediated by different subtypes of cyclooxygenase in AMI induced heart failure rats.

Authors:  Jing Wang; Chun Li; Yuan Cao; Qiyan Wang; Linghui Lu; Hong Chang; Yan Wu; Jing Han; Wei Wang; Pengfei Tu; Yong Wang
Journal:  BMC Complement Altern Med       Date:  2015-10-07       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.